This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for Boeing, Texas Instruments & General Dynamics
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Texas Instruments (TXN) and General Dynamics (GD).
Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.
The Most Spectacular Earnings Charts This Week
by Tracey Ryniec
Investors aren't spooked in these stocks. They have great earnings track records and shares are trading near their highs.
EW, VAR Earnings Due on Oct 23: Here Are Key Predictions
by Zacks Equity Research
Both Edwards Lifesciences (EW) and Varian Medical (VAR) are brimming with prospects despite the current political disarray within the medical instruments space.
Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.
Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $145.51, moving -1.23% from the previous trading session.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
by Zacks Equity Research
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
Bear of the Day: Newmont Mining (NEM)
by Kevin Cook
Gold back above $1200 is encouraging for miners, but the long-term bear market is still in charge
Edwards Lifesciences (EW) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Edwards Lifesciences (EW) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EW) Outperforming Other Medical Stocks This Year?
Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Edwards Begins US CENTERA Study, Reintroduces Valve in Europe
by Zacks Equity Research
Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
4 MedTech Stocks to Counter Mounting US-China Trade Tensions
by Sweta Jaiswal
In the wake of the impact of the U.S.-China trade war on the MedTech space, we have doubled down on some stocks which offer a safe haven to investors.
Here's Why You Should Add Edwards Lifesciences Right Away
by Zacks Equity Research
We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.
Edwards Lifesciences (EW) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Here's Why You Should Steer Clear of AmerisourceBergen Now (Revised)
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q2.
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
by Zacks Equity Research
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.